J u m p t o c o n t e n t
M a i n m e n u
M a i n m e n u
N a v i g a t i o n
● M a i n p a g e
● C o n t e n t s
● C u r r e n t e v e n t s
● R a n d o m a r t i c l e
● A b o u t W i k i p e d i a
● C o n t a c t u s
● D o n a t e
C o n t r i b u t e
● H e l p
● L e a r n t o e d i t
● C o m m u n i t y p o r t a l
● R e c e n t c h a n g e s
● U p l o a d f i l e
S e a r c h
Search
A p p e a r a n c e
● C r e a t e a c c o u n t
● L o g i n
P e r s o n a l t o o l s
● C r e a t e a c c o u n t
● L o g i n
P a g e s f o r l o g g e d o u t e d i t o r s l e a r n m o r e
● C o n t r i b u t i o n s
● T a l k
( T o p )
1
R e s e a r c h
2
U n a p p r o v e d m a r k e t i n g
3
R e f e r e n c e s
T o g g l e t h e t a b l e o f c o n t e n t s
B P C - 1 5 7
1 l a n g u a g e
● Р у с с к и й
E d i t l i n k s
● A r t i c l e
● T a l k
E n g l i s h
● R e a d
● E d i t
● V i e w h i s t o r y
T o o l s
T o o l s
A c t i o n s
● R e a d
● E d i t
● V i e w h i s t o r y
G e n e r a l
● W h a t l i n k s h e r e
● R e l a t e d c h a n g e s
● U p l o a d f i l e
● S p e c i a l p a g e s
● P e r m a n e n t l i n k
● P a g e i n f o r m a t i o n
● C i t e t h i s p a g e
● G e t s h o r t e n e d U R L
● D o w n l o a d Q R c o d e
● W i k i d a t a i t e m
P r i n t / e x p o r t
● D o w n l o a d a s P D F
● P r i n t a b l e v e r s i o n
A p p e a r a n c e
F r o m W i k i p e d i a , t h e f r e e e n c y c l o p e d i a
BPC-157 (also known as PL 14736) is an oligopeptide consisting of a chain of fifteen amino acids. It has the amino acid sequence Gly -Glu -Pro -Pro-Pro-Gly-Lys -Pro-Ala -Asp -Asp-Ala-Gly-Leu -Val .[1] This peptide has a molecular formula of C62 H 98 N 16 O 22 . The PUBCHEM ID is CID 9941957.[2]
The peptide is banned by the World Anti-Doping Agency in 2022 under the S0 category of non-exempt substances.[3]
Research
[ edit ]
There are some tentative pre-clinical studies on animals and in vitro suggesting possible benefit in wound healing and bowel disorders although all of these studies come from a single research group.[4] [5]
Unapproved marketing
[ edit ]
BPC 157 is marketed in functional medicine , although, FDA approval is not issued yet for it to be used in standard medicine.[6]
References
[ edit ]
^ Jelovac, Nikola; Sikiric, Predrag; Rucman, Rudolf; Petek, Marijan; Marovic, Anton; Perovic, Darko; Seiwerth, Sven; Mise, Stjepan; Turkovic, Branko; Dodig, Goran; Miklic, Pavle; Buljat, Gojko; Prkacin, Ingrid (1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology . 379 (1 ): 19–31. doi :10.1016/S0014-2999(99 )00486-0 . PMID 10499368 .
^ "PUBCHEM" . pubchem.ncbi.nlm.nih.gov . Retrieved 1 March 2021 .
^ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" (PDF) . World Anti-Doping Agency . WADA. Retrieved 21 February 2022 .
^ Sikiric, P.; Seiwerth, S.; Brcic, L.; Blagaic, A. B.; Zoricic, I.; Sever, M.; Klicek, R.; Radic, B.; Keller, N.; Sipos, K.; Jakir, A.; Udovicic, M.; Tonkic, A.; Kokic, N.; Turkovic, B.; Mise, S.; Anic, T. (2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology . 14 (5–6): 214–21. doi :10.1007/s10787-006-1531-7 . PMID 17186181 . S2CID 24132425 .
^ Cerovecki, Tomislav; Bojanic, Ivan; Brcic, Luka; Radic, Bozo; Vukoja, Ivan; Seiwerth, Sven; Sikiric, Predrag (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research . 28 (9 ): 1155–1161. doi :10.1002/jor.21107 . ISSN 1554-527X . PMID 20225319 . S2CID 22085833 .
^ Sikiric, P; Seiwerth, S; Rucman, R; Kolenc, D; Vuletic, LB; Drmic, D; Grgic, T; Strbe, S; Zukanovic, G; Crvenkovic, D; Madzarac, G; Rukavina, I; Sucic, M; Baric, M; Starcevic, N; Krstonijevic, Z; Bencic, ML; Filipcic, I; Rokotov, DS; Vlainic, J (2016). "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications" . Current Neuropharmacology . 14 (8 ): 857–865. doi :10.2174/1570159x13666160502153022 . PMC 5333585 . PMID 27138887 .
R e t r i e v e d f r o m " https://en.wikipedia.org/w/index.php?title=BPC-157&oldid=1226444770 "
C a t e g o r y :
● P e p t i d e t h e r a p e u t i c s
H i d d e n c a t e g o r i e s :
● A r t i c l e s w i t h s h o r t d e s c r i p t i o n
● S h o r t d e s c r i p t i o n i s d i f f e r e n t f r o m W i k i d a t a
● T h i s p a g e w a s l a s t e d i t e d o n 3 0 M a y 2 0 2 4 , a t 1 7 : 4 7 ( U T C ) .
● T e x t i s a v a i l a b l e u n d e r t h e C r e a t i v e C o m m o n s A t t r i b u t i o n - S h a r e A l i k e L i c e n s e 4 . 0 ;
a d d i t i o n a l t e r m s m a y a p p l y . B y u s i n g t h i s s i t e , y o u a g r e e t o t h e T e r m s o f U s e a n d P r i v a c y P o l i c y . W i k i p e d i a ® i s a r e g i s t e r e d t r a d e m a r k o f t h e W i k i m e d i a F o u n d a t i o n , I n c . , a n o n - p r o f i t o r g a n i z a t i o n .
● P r i v a c y p o l i c y
● A b o u t W i k i p e d i a
● D i s c l a i m e r s
● C o n t a c t W i k i p e d i a
● C o d e o f C o n d u c t
● D e v e l o p e r s
● S t a t i s t i c s
● C o o k i e s t a t e m e n t
● M o b i l e v i e w